Company Overview

Alpha Tau Medical Ltd. is a clinical-stage medical device company focused on the development of targeted cancer therapies using alpha particle radiation. The company operates within the oncology medical device and radiation therapy industries, with a core emphasis on solid tumor treatment. Its proprietary technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver high-energy alpha radiation directly to tumors while minimizing damage to surrounding healthy tissue, addressing limitations of conventional external beam radiation and systemic radiotherapies.

The company’s primary activities are research, development, and clinical validation of Alpha DaRT for multiple cancer indications, including recurrent head and neck cancer and skin cancers, with additional studies underway in other solid tumors. Alpha Tau Medical does not currently generate significant commercial revenue and remains focused on advancing its technology through regulatory pathways. Founded in 2016, the company emerged from academic research conducted in Israel and transitioned into a publicly traded company following its business combination with a special purpose acquisition company, marking its evolution from early-stage research to late-stage clinical development.

Business Operations

Alpha Tau Medical’s operations are centered on a single reportable business focused on the development and clinical deployment of the Alpha DaRT platform, which represents its core technology and primary value driver. The company designs and manufactures proprietary alpha-emitting sources and delivery systems intended for interstitial placement within tumors. Revenue generation to date has been limited and primarily related to research collaborations and clinical activity support, as the company has not yet commercialized a product.

Operationally, Alpha Tau Medical conducts clinical trials across North America, Europe, and Israel, supported by regulatory approvals for investigational use. The company operates through subsidiaries including Alpha Tau Medical Inc. in the United States, which supports clinical development, regulatory engagement, and future commercialization planning. Manufacturing and technology development capabilities are closely controlled to protect intellectual property and ensure regulatory compliance, with no reliance on large-scale commercial manufacturing partners at this stage.

Strategic Position & Investments

Strategically, Alpha Tau Medical is focused on achieving regulatory approval for Alpha DaRT in initial oncology indications and expanding its clinical pipeline into additional tumor types. Growth initiatives center on advancing late-stage clinical trials, engaging with regulators in key markets, and building clinical evidence to support broader adoption by oncologists and radiation therapy centers. The company positions Alpha DaRT as a differentiated modality that can complement or, in some cases, replace existing radiation or surgical options for difficult-to-treat tumors.

A major corporate milestone was its public listing on the Nasdaq through the acquisition of Alpha Tau Medical Ltd. by Healthcare Capital Corp., providing capital to fund ongoing trials and operational expansion. The company continues to invest heavily in clinical research, device optimization, and intellectual property development rather than acquiring external businesses, and it does not maintain a diversified investment portfolio outside its core technology focus.

Geographic Footprint

Alpha Tau Medical is headquartered in Israel, where its core research and development activities originated and where key scientific leadership remains based. The company maintains a growing presence in North America, particularly the United States, which is a primary target market and a central location for regulatory strategy and clinical trials.

In addition to Israel and the United States, Alpha Tau Medical has operational and clinical trial activities across Europe, reflecting a strategy to generate multinational clinical data and engage with multiple regulatory frameworks. This international footprint supports its long-term objective of global commercialization, although the company currently does not report material revenue from any geographic region.

Leadership & Governance

Alpha Tau Medical was founded by scientists and entrepreneurs with backgrounds in nuclear physics, oncology, and medical device development, shaping a leadership philosophy centered on scientifically driven innovation and clinical validation. The management team emphasizes rigorous clinical evidence, close collaboration with academic medical centers, and long-term value creation through regulatory success rather than near-term commercialization.

Key members of the leadership team include:

• Itzhak Shechter – Chief Executive Officer
• Uzi Sofer – Founder and Chief Technology Officer
• Prof. Itzhak Kelson – Co-Founder and Chief Medical Officer

The company is governed by a board of directors with experience in healthcare, capital markets, and medical technology, aligning oversight with its status as a publicly traded, clinical-stage company.